TAVO-PLUS-CD3

**TAVO-PLUS-CD3** is an investigational next-generation intratumoral cancer immunotherapy developed by OncoSec Medical. It is a **DNA plasmid-based gene therapy** administered by **intratumoral electroporation** and designed to combine plasmid-encoded **interleukin-12** activity with **membrane-bound anti-CD3** to enhance T-cell engagement within the tumor microenvironment and augment T-cell mediated tumor cell killing. Based on the provided context, it has been studied preclinically for **solid tumors**, where it showed enhanced anti-tumor immune responses and increased effector memory T cells relative to the earlier TAVO formulation.

Other names

TAVO+-αCD3